Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
20 hedge funds and large institutions have $19.4M invested in Achilles Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
11% more funds holding
Funds holding: 18 → 20 (+2)
8% more capital invested
Capital invested by funds: $17.9M → $19.4M (+$1.44M)
5.32% more ownership
Funds ownership: 48.09% → 53.41% (+5.3%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$52.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.6K |
| 3 |
VF
Virtu Financial
New York
|
+$33.9K |
| 4 |
Millennium Management
New York
|
+$12.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$390K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$43.4K |
| 3 |
Morgan Stanley
New York
|
-$42.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$19.2K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$11.9K |
ACHL Hedge Fund Activity: Q4 2023 in Review
20 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q4 2023, worth a combined $19.4M — up 8.1% from $17.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ACHL positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $52.7K. The largest seller was Baker Bros. Advisors, cutting an estimated $390K.
- 20 institutional investors held Achilles Therapeutics (ACHL) as of Q4 2023, up from 18 in Q3 2023.
- Funds reported $19.4M of Achilles Therapeutics stock for Q4 2023, up 8.1% quarter-over-quarter.
- 5 funds opened new Achilles Therapeutics positions in Q4 2023 and 3 closed out, a net change of +2 holders.
- The largest Achilles Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $52.7K added.
- The largest Achilles Therapeutics seller in Q4 2023 was Baker Bros. Advisors, an estimated $390K sold.
Based on aggregated 13F filings for Q4 2023.